Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets Crossbow Therapeutics today announced the nomination of its first development candidate, CBX-250, a T-cell engager for the treatment of myeloid leukemia.